Screener
Jazz Pharmaceuticals JAZZ Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
| Deferred tax liabilities, net | 547.7 | 594.5 |
| Other non-current liabilities | 161.5 | 124.4 |
| Commitments and contingencies (Note 10) | ||
| Shareholders’ equity: | ||
| Ordinary shares | — | — |
| Non-voting euro deferred shares | 0.1 | 0.1 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's other non-current liabilities?
- Jazz Pharmaceuticals (JAZZ) reported other non-current liabilities of $161.5M in Q1 2026.
- How has Jazz Pharmaceuticals's other non-current liabilities changed year-over-year?
- Jazz Pharmaceuticals's other non-current liabilities increased by 77.2% year-over-year, from $91.12M to $161.5M.
- What is the long-term trend for Jazz Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's other non-current liabilities has grown at a 4.2% compound annual growth rate (CAGR), from $101.15M to $124.4M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Jazz Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude